Home > Cardiology > ESC 2021 > Dramatic reduction of CV risk with vaccine-like strategy to lower LDL

Dramatic reduction of CV risk with vaccine-like strategy to lower LDL

Presented By
Prof. Brian Ference, University of Cambridge, UK
Conference
ESC 2021
Trial
NATURE-PCSK9
The NATURE-PCSK9 study revealed that a yearly vaccine-like approach with PCSK9 small-interfering RNA can reduce cardiovascular events by up to two thirds. The motto ‘the earlier the better’ also holds true for low-density lipoprotein (LDL) reduction [1]. Individuals who inherit LDL-lowering variants in the PCSK9 are known to have large reductions in lifetime risk of cardiovascular events. In a previous study, a single dose of a PCSK9 small-interfering RNA (siRNA) led to a durable reduction of LDL concentrations over 1 year ranging from 29.5% to 38.7% [2]. “The availability of a yearly dose of siRNA directed against PCSK9 allows us to use this strategy in a vaccine-like approach,” explained Prof. Brian Ference (University of Cambridge, UK). The primary objective of the NATURE-PCSK9 study was to compare the potential clinical benefit of a yearly vaccine-like strategy using siRNA beginning at age 30, 40, 50, or 60 years (expected to re...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on